Chris Gagliardi

Chris is a Principal at Sanofi Ventures, having joined the team in 2017 following a background in life science and healthcare consulting. Prior to Sanofi Ventures, he spent three years at L.E.K. Consulting, where he advised pharmaceutical and biotechnology clients on corporate strategy, due diligence, commercial planning, and asset valuation across therapeutics, R&D services, and API manufacturing.

Chris serves as a Director on the Board of QuantX and represents Sanofi on the Boards of AdvanCell, Sudo Biosciences, i2O Therapeutics, and Minervax. He also serves as a Board Observer for Atalanta Therapeutics, Avilar Therapeutics, Diagonal Therapeutics, Matchpoint Therapeutics, and Nextpoint Therapeutics. Outside of his investment activities, Chris serves on the Board of Trustees of Roger Williams University.

Chris completed a postdoctoral fellowship at Harvard University and holds a Ph.D. in Chemistry from the University of North Carolina at Chapel Hill, as well as a B.S. in Biology and Chemistry from Roger Williams University.